FDA Approves Monthly Injectable Drug For Treating Three Types Of Immune-Related Arthritis (PharmaceuticalOnline)

The U.S. Food and Drug Administration recently approved Simponi (golimumab), a monthly treatment for adults with moderate-to-severe rheumatoid arthritis, active psoriatic arthritis, and active ankylosing spondylitis.